Abstract: Provided is a manufacturing method for an array substrate and an array substrate. The manufacturing method for an array substrate comprises: depositing a gate metal layer, and carrying out a first pass of photolithography to form a gate; depositing a gate insulation layer, a first semiconductor layer, a second semiconductor layer, a first barrier layer, a second barrier layer and a source-drain metal layer in sequence, carrying out a second pass of photolithography to form an active island, meanwhile forming a source and a drain; depositing a passivation layer, and carrying out a third pass of photolithography to form a conductive via in the passivation layer on the drain; and depositing a transparent conductive layer, and carrying out a fourth pass of photolithography to form the transparent conductive layer into the pixel electrode and enable the pixel electrode to be communicated with the drain through the conductive via.

Abstract: This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.

Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.

Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

Abstract: This document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. This document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.

Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000.

Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

Abstract: This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also relates to compositions comprising a non-covalently bound complex comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions consisting essentially of ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: This document relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition consisting essentially of docetaxel, proteins comprising a human serum albumin, and sodium caprylate, wherein the docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:70 to about 1:300, and wherein the composition does not contain sodium N-acetyltryptophanate. This document also relates to a composition comprising docetaxel, proteins comprising a human serum albumin, and sodium N-acetyltryptophanate, wherein the docetaxel and the human serum albumin in the composition have a ratio by N weight from about 1:80 to less than 1:150.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000.

Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes including Docetaxel and human serum albumin. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000.

Abstract: This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also relates to compositions comprising a non-covalently bound complex comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions consisting essentially of ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000.

Abstract: This document relates to compositions comprising a non-covalently bound complex comprising rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000. This document also relates to compositions comprising rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000. This document also relates to compositions consisting essentially of rolapitant and human serum albumin, wherein the rolapitant and the human serum albumin in the composition have a ratio by weight from about 1:20 to about 1:2000.

Abstract: This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.

Abstract: This document relates to an aqueous composition comprising chlorambucil and human serum albumin, wherein the chlorambucil and the human serum albumin in the aqueous composition have a ratio by weight from about 1:10 to about 1:2000, wherein the aqueous composition comprises at least one water-miscible organic solvent. This document also relates to a solid composition comprising chlorambucil and human serum albumin. This document also relates to a liquid pharmaceutical composition comprising the solid composition comprising the chlorambucil and the human serum albumin, and a pharmaceutically acceptable carrier.